Cancer Genetics, Inc. to Present Results From Three Major

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cancer Genetics, Inc. to Present Results From Three Major Clinical Research Collaborations at USCAP Showcasing the Importance of Genomic Panels for Cancer Identification and Management
  • Collaborations with Keck School of Medicine of USC, University of Alabama School of Medicine, and Westchester Medical Center at New York Medical College provide insight into the diagnosis and management of challenging cancers.
  • The collaborations leverage the power of CGI's unique, proprietary genomic panels, including MatBA ® for diffuse large B-cell lymphoma (DLBCL), which is the only clinically available panel that can stratify lymphoma patients and predict those most likely to relapse.

RUTHERFORD, N.J., March 23, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) ("CGI" or "the company") announced today that it will present three posters at USCAP, the annual meeting of the United States and Canadian Academy of Pathology, March 23-24 at the Hynes Convention Center in Boston, MA. The presentations will feature the results of several clinical research collaborations aimed at providing better insight into the molecular basis of poorly understood cancers in order to drive improved diagnosis and patient management. Each of the collaborations leveraged CGI's proprietary genomic panels for their investigation.

Cancer Genetics' collaboration with the Keck School of Medicine of University of Southern California (USC), examines the relationship of genetic markers and pathologic features to clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients. Results will be presented on Monday, March 23 at 1:00 pm ET in a poster entitled "MYC/TP53 Coexpression and Loss of 17p13 are Independently Associated with Inferior Survival in Diffuse Large B-Cell Lymphoma (DLBCL)" by Charles Ma, Ph.D., principal research scientist at Cancer Genetics, Inc. DLBCL is the most common form of non-Hodgkin lymphoma (NHL), representing 25-30% of all NHL cases. As the population continues to age, incidence of DLBCL is expected to rise, creating increasing demand for genetic tests such as CGI's MatBA ® -DLBCL.  CGI's genomic panel for DLBCL is better able to differentiate between patients that are likely to be cured from those that are likely to relapse.

Results of a collaboration with the University of Alabama (UAB) School of Medicine on primary central nervous system lymphomas (PCNSL) will be presented in a poster, "Molecular Cytogenetic Features of Primary Central Nervous System Lymphoma" by Deniz Peker, MD, of the UAB School of Medicine. Primary central nervous system lymphomas (PCNSL) are a group of poorly understood aggressive cancers. This study used CGI's array-CGH (comparative genomic hybridization) techniques to identify chromosomal changes in PCNSL to better understand the biomarkers associated with these diseases. The poster will be presented on Monday, March 23 at 1:00 pm ET.

A third poster, "Immunohistochemistry Stain and Molecular Genetic Study on Hemangioblastoma: An Indication of Anti-VEGF Target Therapy," will report results of a study conducted in collaboration with Westchester Medical Center at New York Medical College. Hemangioblastomas are slow-growing tumors of the central nervous system for which no targeted therapies are currently available. Anti-VEGF target therapy was investigated as a possible treatment for hemangioblastomas due to its morphological similarity to clear cell renal cell carcinoma. CGI's proprietary array-CGH panel UroGenRA®-Kidney was critical in assessing the comparative genomic gains and losses involved. The poster will be presented by Sabina Babayeva from Westchester Medical Center on Tuesday, March 24 at 9:30 am ET.

According to Panna Sharma, CEO of Cancer Genetics, Inc., "The research results being presented at USCAP this week demonstrate our continued focus on the validation of our unique technology to improve patient management. Our tests are helping researchers to develop novel and targeted insights into the molecular basis of poorly understood cancers to drive improvements in diagnosis and patient management."

The USCAP meeting will take place at the Hynes Convention Center in Boston, March 21-27. Representatives from the company will be exhibiting in booth 716 at the 2015 USCAP Annual Meeting Expo from March 22-26. 

About Cancer Genetics

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and  HPV-associated cancers . We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:
            Internet:  http://www.cancergenetics.com
            Twitter:  @Cancer_Genetics
            Facebook:  www.facebook.com/CancerGenetics

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future developments in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Media Relations Sandeep Kalelkar, Ph.D. Cancer Genetics, Inc. 919-653-5543 Investor Relations Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 159

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into Carvana's Growing Options Market Activity

Updated Category News Views 105

Carvana's Options Market Activity Investors with substantial capital are displaying a bullish sentiment towards Carvana Co (NYSE: CVNA). This developing trend in the options market is noteworthy and shouldn't be overlooked by market participants. Recent analyses have revealed an intriguing series of activities that hint at significant upcoming developments for Carvana....

Continue Reading
Road Warrior Expands Network with Big Acquisitions

Updated Category News Views 30

A Heavy-Duty Play: Road Warrior's Big Moves You might think in the world of heavy-duty parts and service, things move like a freight train—slow and steady. But here comes Road Warrior Parts & Service, full steam ahead with a string of acquisitions that are shaking up the landscape. If you've been snoozing on this sector, it's time to wake up. The Acquisitions That Are...

Continue Reading
Foresight Group Commences Strategic Share Buyback Programme

Updated Category News Views 358

Foresight Group Commences Strategic Share Buyback Programme Foresight Group Holdings Limited (LSE: FSG), a well-respected leader in investment management for real assets, is pleased to announce a new initiative as part of its ongoing commitment to creating shareholder value. This new share buyback programme, announced recently, underscores its proactive approach to...

Continue Reading
Carvana's New Delivery Service Lifts Stock Prices Significantly

Updated Category News Views 164

Overview of Carvana's Recent Stock Movement Carvana Co (NYSE: CVNA) has seen its stock rise as it introduces new service options. Recently, the company extended its same-day vehicle delivery feature to customers in the San Diego area, marking a significant enhancement in its operations. By allowing locals to receive their purchased vehicles on the same day they place an...

Continue Reading
AI-Powered Travel Transformation in Norway Revealed

Updated Category News Views 130

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Continue Reading